Logo image of GERN

GERON CORP (GERN) Stock Fundamental Analysis

NASDAQ:GERN - Nasdaq - US3741631036 - Common Stock - Currency: USD

2.57  -0.06 (-2.28%)

After market: 2.57 0 (0%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to GERN. GERN was compared to 571 industry peers in the Biotechnology industry. GERN has a bad profitability rating. Also its financial health evaluation is rather negative. GERN is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

GERN had negative earnings in the past year.
In the past year GERN has reported a negative cash flow from operations.
In the past 5 years GERN always reported negative net income.
GERN had a negative operating cash flow in each of the past 5 years.
GERN Yearly Net Income VS EBIT VS OCF VS FCFGERN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -50M -100M -150M

1.2 Ratios

GERN has a Return On Assets (-45.22%) which is in line with its industry peers.
GERN has a Return On Equity (-68.83%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -45.22%
ROE -68.83%
ROIC N/A
ROA(3y)-57.52%
ROA(5y)-48.38%
ROE(3y)-114.5%
ROE(5y)-86.01%
ROIC(3y)N/A
ROIC(5y)N/A
GERN Yearly ROA, ROE, ROICGERN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -50 -100 -150

1.3 Margins

GERN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GERN Yearly Profit, Operating, Gross MarginsGERN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -20K -40K -60K -80K

More info and screens

3

2. Health

2.1 Basic Checks

GERN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, GERN has more shares outstanding
GERN has more shares outstanding than it did 5 years ago.
The debt/assets ratio for GERN has been reduced compared to a year ago.
GERN Yearly Shares OutstandingGERN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M
GERN Yearly Total Debt VS Total AssetsGERN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of -0.17, we must say that GERN is in the distress zone and has some risk of bankruptcy.
GERN's Altman-Z score of -0.17 is fine compared to the rest of the industry. GERN outperforms 62.88% of its industry peers.
GERN has a Debt/Equity ratio of 0.04. This is a healthy value indicating a solid balance between debt and equity.
GERN has a worse Debt to Equity ratio (0.04) than 61.99% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Altman-Z -0.17
ROIC/WACCN/A
WACC9.45%
GERN Yearly LT Debt VS Equity VS FCFGERN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 2.89 indicates that GERN has no problem at all paying its short term obligations.
GERN's Current ratio of 2.89 is on the low side compared to the rest of the industry. GERN is outperformed by 67.14% of its industry peers.
A Quick Ratio of 2.74 indicates that GERN has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 2.74, GERN is doing worse than 66.79% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.89
Quick Ratio 2.74
GERN Yearly Current Assets VS Current LiabilitesGERN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

More info and screens

5

3. Growth

3.1 Past

GERN shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 5.88%.
GERN shows a strong growth in Revenue. In the last year, the Revenue has grown by 9409.68%.
Measured over the past years, GERN shows a very negative growth in Revenue. The Revenue has been decreasing by -26.03% on average per year.
EPS 1Y (TTM)5.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
Revenue 1Y (TTM)9409.68%
Revenue growth 3Y-1.76%
Revenue growth 5Y-26.03%
Sales Q2Q%17138.41%

3.2 Future

The Earnings Per Share is expected to grow by 30.55% on average over the next years. This is a very strong growth
GERN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 429.91% yearly.
EPS Next Y14.69%
EPS Next 2Y32.99%
EPS Next 3Y35.99%
EPS Next 5Y30.55%
Revenue Next Year26300.3%
Revenue Next 2Y3106.33%
Revenue Next 3Y1134.83%
Revenue Next 5Y429.91%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
GERN Yearly Revenue VS EstimatesGERN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B 2B
GERN Yearly EPS VS EstimatesGERN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 0.5 1

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for GERN. In the last year negative earnings were reported.
Also next year GERN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GERN Price Earnings VS Forward Price EarningsGERN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GERN Per share dataGERN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4

4.3 Compensation for Growth

A more expensive valuation may be justified as GERN's earnings are expected to grow with 35.99% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.99%
EPS Next 3Y35.99%

More info and screens

0

5. Dividend

5.1 Amount

GERN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GERON CORP

NASDAQ:GERN (2/21/2025, 8:23:23 PM)

After market: 2.57 0 (0%)

2.57

-0.06 (-2.28%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/bmo
Earnings (Next)02-26 2025-02-26/bmo
Inst Owners81.67%
Inst Owner Change-96.4%
Ins Owners0.09%
Ins Owner Change-0.31%
Market Cap1.55B
Analysts85.33
Price Target7.88 (206.61%)
Short Float %12.35%
Short Ratio6.36
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)29.57%
Min EPS beat(2)5.99%
Max EPS beat(2)53.15%
EPS beat(4)4
Avg EPS beat(4)21.2%
Min EPS beat(4)5.99%
Max EPS beat(4)53.15%
EPS beat(8)7
Avg EPS beat(8)19.01%
EPS beat(12)9
Avg EPS beat(12)14.37%
EPS beat(16)10
Avg EPS beat(16)10.57%
Revenue beat(2)2
Avg Revenue beat(2)130.18%
Min Revenue beat(2)45.76%
Max Revenue beat(2)214.6%
Revenue beat(4)3
Avg Revenue beat(4)324.94%
Min Revenue beat(4)-66.74%
Max Revenue beat(4)1106.15%
Revenue beat(8)4
Avg Revenue beat(8)165.01%
Revenue beat(12)7
Avg Revenue beat(12)255.48%
Revenue beat(16)10
Avg Revenue beat(16)211.66%
PT rev (1m)1.46%
PT rev (3m)7.75%
EPS NQ rev (1m)17.23%
EPS NQ rev (3m)-25%
EPS NY rev (1m)3.07%
EPS NY rev (3m)-3.37%
Revenue NQ rev (1m)-0.49%
Revenue NQ rev (3m)0.98%
Revenue NY rev (1m)1.12%
Revenue NY rev (3m)3.18%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 52.7
P/FCF N/A
P/OCF N/A
P/B 5.32
P/tB 5.32
EV/EBITDA N/A
EPS(TTM)-0.32
EYN/A
EPS(NY)-0.08
Fwd EYN/A
FCF(TTM)-0.36
FCFYN/A
OCF(TTM)-0.36
OCFYN/A
SpS0.05
BVpS0.48
TBVpS0.48
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -45.22%
ROE -68.83%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-57.52%
ROA(5y)-48.38%
ROE(3y)-114.5%
ROE(5y)-86.01%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.07
Health
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 170.74%
Cap/Sales 2.99%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.89
Quick Ratio 2.74
Altman-Z -0.17
F-Score3
WACC9.45%
ROIC/WACCN/A
Cap/Depr(3y)143.84%
Cap/Depr(5y)272.97%
Cap/Sales(3y)145.66%
Cap/Sales(5y)137.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)5.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
EPS Next Y14.69%
EPS Next 2Y32.99%
EPS Next 3Y35.99%
EPS Next 5Y30.55%
Revenue 1Y (TTM)9409.68%
Revenue growth 3Y-1.76%
Revenue growth 5Y-26.03%
Sales Q2Q%17138.41%
Revenue Next Year26300.3%
Revenue Next 2Y3106.33%
Revenue Next 3Y1134.83%
Revenue Next 5Y429.91%
EBIT growth 1Y-14.52%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-1.25%
EBIT Next 3Y35.74%
EBIT Next 5YN/A
FCF growth 1Y-88.63%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-88.52%
OCF growth 3YN/A
OCF growth 5YN/A